BACKGROUND: The second-generation cryoballoon (cryoballoon Advance; CB-A) offers excellent outcomes on the mid-term follow-up. To the best of our knowledge, little is known regarding the long-term outcome after CB-A ablation for paroxysmal atrial fibrillation (AF). OBJECTIVE: The aim of the study was to evaluate the freedom from recurrence of AF during a 3-year follow-up period, among consecutive patients having undergone pulmonary vein isolation (PVI) with the CB-A for paroxysmal AF (PAF). METHODS: Consecutive patients with drug-resistant PAF who underwent PVI using CB-A as an index procedure formed the study group. Patients were evaluated with holter ECG recordings at 1, 3, 6 and 12 months and subsequent follow-up was biannual or based on the clinical status and at the physician discretion. RESULTS: Seventy-six consecutive patients were enrolled. Of these patients, 6 were excluded because of lack of long-term follow-up. A total of 70 patients [44 male (63%); mean age 57.9 ± 14.5 years] with a mean follow-up of 38.0 ± 7.4 months were finally included. In total, 278 PVs were depicted on the pre-procedural CT scan. All PVs (100%) could be isolated with the CB-A only. The freedom from AF without antiarrhythmic drug (AADs) after a single procedure was 71.5% of patients at a mean 38.0 ± 7.4 months follow-up. If including repeat procedures, 80% of the patients were free from AF recurrence after 1.11 ± 0.32 procedures without AADs. CONCLUSION: The second-generation cryoballoon offers long-term freedom from PAF in 71.5% of treated patients with a single procedure without AADs on a 3-year follow-up period.
BACKGROUND: The second-generation cryoballoon (cryoballoon Advance; CB-A) offers excellent outcomes on the mid-term follow-up. To the best of our knowledge, little is known regarding the long-term outcome after CB-A ablation for paroxysmal atrial fibrillation (AF). OBJECTIVE: The aim of the study was to evaluate the freedom from recurrence of AF during a 3-year follow-up period, among consecutive patients having undergone pulmonary vein isolation (PVI) with the CB-A for paroxysmal AF (PAF). METHODS: Consecutive patients with drug-resistant PAF who underwent PVI using CB-A as an index procedure formed the study group. Patients were evaluated with holter ECG recordings at 1, 3, 6 and 12 months and subsequent follow-up was biannual or based on the clinical status and at the physician discretion. RESULTS: Seventy-six consecutive patients were enrolled. Of these patients, 6 were excluded because of lack of long-term follow-up. A total of 70 patients [44 male (63%); mean age 57.9 ± 14.5 years] with a mean follow-up of 38.0 ± 7.4 months were finally included. In total, 278 PVs were depicted on the pre-procedural CT scan. All PVs (100%) could be isolated with the CB-A only. The freedom from AF without antiarrhythmic drug (AADs) after a single procedure was 71.5% of patients at a mean 38.0 ± 7.4 months follow-up. If including repeat procedures, 80% of the patients were free from AF recurrence after 1.11 ± 0.32 procedures without AADs. CONCLUSION: The second-generation cryoballoon offers long-term freedom from PAF in 71.5% of treated patients with a single procedure without AADs on a 3-year follow-up period.
Authors: Thomas Neumann; Maciej Wójcik; Alexander Berkowitsch; Damir Erkapic; Sergey Zaltsberg; Harald Greiss; Dimitri Pajitnev; Stefan Lehinant; Jörn Schmitt; Christian W Hamm; Heinz F Pitschner; Malte Kuniss Journal: Europace Date: 2013-02-17 Impact factor: 5.214
Authors: Kudret Aytemir; Kadri Murat Gurses; Muhammed Ulvi Yalcin; Duygu Kocyigit; Muhammet Dural; Banu Evranos; Hikmet Yorgun; Ahmet Hakan Ates; Mehmet Levent Sahiner; Ergun Baris Kaya; Mehmet Ali Oto Journal: Europace Date: 2014-11-05 Impact factor: 5.214
Authors: Alexander Fürnkranz; Stefano Bordignon; Boris Schmidt; Melanie Gunawardene; Britta Schulte-Hahn; Verena Urban; Frank Bode; Bernd Nowak; Julian K R Chun Journal: J Cardiovasc Electrophysiol Date: 2013-02-11
Authors: Valentina DE Regibus; Giacomo Mugnai; Darragh Moran; Burak Hünük; Erwin Ströker; Ebru Hacioglu; Diego Ruggiero; Hugo Enrique Coutiño-Moreno; Ken Takarada; Pedro Brugada; Carlo DE Asmundis; Gian-Battista Chierchia Journal: J Cardiovasc Electrophysiol Date: 2016-04-22
Authors: Ghazala Irfan; Carlo de Asmundis; Giacomo Mugnai; Jan Poelaert; Christian Verborgh; Vincent Umbrain; Stefan Beckers; Ebru Hacioglu; Burak Hunuk; Vedran Velagic; Erwin Stroker; Pedro Brugada; Gian-Battista Chierchia Journal: Europace Date: 2015-12-23 Impact factor: 5.214
Authors: Ivan Zeljkovic; Sven Knecht; Florian Spies; Tobias Reichlin; Stefan Osswald; Michael Kühne; Christian Sticherling Journal: J Interv Card Electrophysiol Date: 2020-01-07 Impact factor: 1.900
Authors: Lara Wagner; Fabrice F Darche; Dierk Thomas; Patrick Lugenbiel; Panagiotis Xynogalos; Svenja Seide; Eberhard P Scholz; Hugo A Katus; Patrick A Schweizer Journal: Clin Res Cardiol Date: 2020-05-13 Impact factor: 5.460
Authors: Makoto Sano; Christian-Hendrik Heeger; Vanessa Sciacca; Niels Große; Ahmad Keelani; Behzad Hassan Hosseiny Fahimi; Huong Lan Phan; Samuel Reincke; Ben Brüggemann; Thomas Fink; Spyridon Liosis; Julia Vogler; Charlotte Eitel; Roland Richard Tilz Journal: J Interv Card Electrophysiol Date: 2020-07-07 Impact factor: 1.900